Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia

European Journal of Pharmacology

Volumn 181, Issue 3, 1990, Pages 175-186

  See, Ronald E ^a   Ellison, Gaylord ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

(Rodent models); Clozapine; Haloperidol; Neuroleptics (chronic); Raclopride; Tardive dyskinesia

Indexed keywords

CLOZAPINE; HALOPERIDOL; RACLOPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; MOUTH; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TARDIVE DYSKINESIA; VIDEORECORDING;

ANIMAL; BEHAVIOR, ANIMAL; BODY WEIGHT; CLOZAPINE; COMPARATIVE STUDY; DIBENZAZEPINES; DISEASE MODELS, ANIMAL; DRINKING; DYSKINESIA, DRUG-INDUCED; FEMALE; FOURIER ANALYSIS; HALOPERIDOL; RACLOPRIDE; RATS; RATS, INBRED STRAINS; SALICYLAMIDES; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025279451     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(90)90077-J     Document Type: Article

References (53)

1. Tremographic studies in tardive dyskinesia
2. Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia
3. Preferential effect of noncataleptogenic neuroleptics on mesolimbic dopaminergic function
4. Antipsychotic drug action: clinical, biochemical, and pharmacological evidence for site specificity of action
5. The risks and benefits of clozapine versus chlorpromazine
6. Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine
7. 3H]spiperone binding of 3,5-disubstituted N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxysalicylamines
8. Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia
9. Tremorous mouth movements in rats administered chronic neuroleptics
10. Clinical research techniques in tardive dyskinesia
11. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs
12. An open label trial of raclopride in acute schizophrenia
13. Withdrawal syndromes associated with antipsychotic drugs
14. Sulpiride in tardive dyskinesia
15. Clozapine and haloperidol in single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia
16. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration
17. Raclopride a new selective ligand for the dopamine-D2 receptors
18. Effects of remoxipride and some related new substituted salicylamides on rat brain receptors
19. Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons
20. Effects of raclopride on exploratory motor activity, treadmill locomotion, conditioned avoidance behaviour and catalepsy in rats: Behavioural profile comparisons between raclopride, haloperidol and preclamol
21. New selective dopamine D-2 antagonists as antipsychotic agents
22. Receptor-binding profiles of neuroleptics
23. Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats
24. Therapeutic strategies against tardive dyskinesia: two decades of experience
25. Dose-dependent increases in rat spontaneous chewing rates during long-term administration of haloperidol but not clozapine
26. Selective D1 and D2 receptor manipulation in cebus monkeys: relevance for dystonia and dyskinesia in humans
27. 3H]spiperone binding in vivo. Biochemical and behavioural evidence for a preferential action on limbic and nigral dopamine receptors
28. Is the low incidence of extrapyramidal side-effects of antipsychotics associated with antimuscarinic properties?
29. Chronic haloperidol effects on radial-arm maze performance and oral movements in rats
30. Neuroleptic-induced oral movements in rats: methodological issues
31. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years
32. Comparison of the effects of haloperidol, remoxipride and reclopride on ‘pre’- and postsynaptic dopamine receptors in the rat brain
33. A systematic review of the pharmacological activities of dopamine antagonists
34. The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions
35. Atypical neuroleptics: clozapine and the benzamides in the prevention and treatment of tardive dyskinesia
36. Atypical neuroleptics clozapine and thioridazine enhance amphetamine-induced stereotypy
37. Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacologic study
38. Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat
39. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat
40. Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine
41. Intermittent and continuous haloperidol regimens produce different types of oral dyskinesias in rats
42. Characteristics of oral movements in rats during and after chronic haloperidol and fluphenazine administration
43. Recording oral activity in rats reveals a long lasting subsentivity to haloperidol as a function of duration of previous haloperidol treatment
44. Dopamine receptors and the dopamine hypothesis of schizophrenia
45. Clozapine, chlorpromazine and placebo in newly hospitalized, acutely schizophrenic patients
46. Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects
47. New neuroleptics and experimental antipsychotics in schizophrenia
48. 3H]spiperone to rat striatal preparations
49. Radioreceptor labeling of pre- and post-synaptic dopamine receptors
50. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptics treatment
51. The machine measured characteristics of tardive dyskinesia